Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Feraheme (ferumoxytol; AMAG Pharmaceuticals) Drug Analysis 2018 -

Research and Markets
Posted on: 21 Feb 18

The "Drug Analysis: Feraheme" drug pipelines has been added to's offering.

Feraheme (ferumoxytol; AMAG Pharmaceuticals) is an intravenous (IV) iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).

The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell. Feraheme, and other iron therapies, are often used in combination with erythropoiesis-stimulating agent (ESA) therapies to increase the number of patients able to achieve target hemoglobin levels compared to patients on ESA therapies alone (Singh, 2008).

Feraheme is comparable to Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria) in terms of safety, efficacy, and dosing frequency, however, it is at a significant commercial disadvantage. Feraheme will have difficulty competing against Injectafer, due to Galenica/Vifor Pharma's dominance of the IV iron market with Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals).

Key Topics Covered:

Product Profiles

Feraheme: Anemia in chronic kidney disease

List of Figures

Figure 1: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24

List of Tables

Table 1: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 21/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.